BioLineRx Other Cashflows From Financing Activities from 2010 to 2025

BLRX Stock  USD 4.47  0.18  3.87%   
BioLineRx Other Cashflows From Financing Activities yearly trend continues to be fairly stable with very little volatility. Other Cashflows From Financing Activities will likely drop to about 20.9 K in 2025. During the period from 2010 to 2025, BioLineRx Other Cashflows From Financing Activities regression line of annual values had significance of  0.78 and arithmetic mean of  2,206,877. View All Fundamentals
 
Other Cashflows From Financing Activities  
First Reported
2010-03-31
Previous Quarter
27 K
Current Value
-5 K
Quarterly Volatility
6.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioLineRx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioLineRx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.3 M, Interest Expense of 9.5 M or Selling General Administrative of 19.4 M, as well as many indicators such as Price To Sales Ratio of 0.7, Dividend Yield of 0.0 or PTB Ratio of 1.81. BioLineRx financial statements analysis is a perfect complement when working with BioLineRx Valuation or Volatility modules.
  
Build AI portfolio with BioLineRx Stock
Check out the analysis of BioLineRx Correlation against competitors.
For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.

Latest BioLineRx's Other Cashflows From Financing Activities Growth Pattern

Below is the plot of the Other Cashflows From Financing Activities of BioLineRx over the last few years. It is BioLineRx's Other Cashflows From Financing Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioLineRx's overall financial position and show how it may be relating to other accounts over time.
Other Cashflows From Financing Activities10 Years Trend
Very volatile
   Other Cashflows From Financing Activities   
       Timeline  

BioLineRx Other Cashflows From Financing Activities Regression Statistics

Arithmetic Mean2,206,877
Coefficient Of Variation434.24
Mean Deviation4,985,421
Median22,000
Standard Deviation9,583,077
Sample Variance91.8T
Range48.6M
R-Value(0.07)
Mean Square Error97.8T
R-Squared0.01
Significance0.78
Slope(150,098)
Total Sum of Squares1377.5T

BioLineRx Other Cashflows From Financing Activities History

202520.9 K
202422 K
2023M
2022 5000.0
202110.9 M
2020M
2019 1000.0

About BioLineRx Financial Statements

BioLineRx investors use historical fundamental indicators, such as BioLineRx's Other Cashflows From Financing Activities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioLineRx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Cashflows From Financing Activities22 K20.9 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.